Cell and gene therapy modifies cells or genetic instructions to treat selected diseases, with benefits, risks and outcomes depending on the condition and… Cell and gene therapy uses living cells, genetic material, or both to address the underlying biology of certain inherited conditions, cancers and Enlarged Spleen and Blood Disorders: Common Links and Next Steps" class="ahp-ilk">blood disorders. These advanced treatments can be highly effective for carefully selected patients, but eligibility, risks, recovery and expected results differ substantially by diagnosis and treatment type. Cell and gene therapy is a group of advanced medical treatments designed to change how cells work or to address a disease-causing genetic change. Rather than only managing symptoms, some of these therapies aim to improve an underlying biological process. They are used for a growing but still limited range of inherited disorders, blood diseases, immune conditions and cancers. Cell therapy generally involves giving patients living cells. Age alone is not the only consideration; overall health and the specific therapy matter. For some inherited blood conditions, specialist assessment may include discussions of sickle cell disease or other genetic disorders in which blood-forming stem cells are central to treatment. It is also helpful to discuss what happens if the therapy does not work as hoped and whether additional treatments remain possible. People with a known inherited disorder, recurrent severe symptoms, a blood disease, or cancer that is not responding as expected should speak with their treating clinician about whether referral to a specialist center is appropriate. Cell and gene therapy requires diagnosis-specific evaluation and should not be pursued without advice from qualified clinicians experienced in the relevant disease area.

Examples often include inherited ... cell disease, where treatment aims to improve how blood cells are made or function. In ophthalmology, gene-based treatments may help selected inherited retinal disorders. In oncology, genetically modified immune cell therapies may be considered for some blood cancers when standard treatment is not enough. Gene therapy may also be discussed in relation to rare pediatric ... Examples often include inherited blood diseases such as thalassemia and some forms of sickle cell disease, where treatment aims to improve how blood cells are made or function. In ophthalmology, gene-based treatments may help selected inherited retinal disorders. In oncology, genetically modified immune cell therapies may be considered for some blood cancers when standard treatment is not enough. Gene therapy may also be discussed in relation to rare pediatric disorders, certain metabolic diseases, and conditions affecting muscles or the nervous system. Yes, some gene therapies are used in children, especially for rare inherited disorders diagnosed early in life. Eligibility depends on the specific condition, treatment approval, disease stage, and specialist assessment. In some cases, gene therapy is considered after standard options such as chemotherapy or other disease-specific treatments have been used. If a patient appears eligible, the care team explains the expected process, possible alternatives, and the need for follow-up. This may involve collection of stem cells or immune cells, laboratory modification, hospital-based infusion, supportive medicines, and repeat testing afterward. For some inherited blood disorders, treatment planning overlaps with advanced hematology care and transfusion management. No two patients follow the same gene therapy path. Some therapies are approved standard treatments for well-defined conditions, while others are available only through clinical trials. The best option depends on the disease, the specific mutation, age, previous treatment history, and the potential balance between benefit and risk. In inherited disorders, treatment may aim to restore a missing protein or improve cell function.

The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.

Gene therapy Casgevy can stop the painful condition if only more doctors knew about it. “She was an African American woman talking to a white male doctor, and so there’s that disconnect in terms of cultural concordance and alignment that drives better health outcomes.” That dynamic, he said, discourages patients from seeking care and undermines the trust needed to get them to advanced therapies. Even established sickle cell treatments suffer from the same awareness gap. “You have something like hydroxyurea that has been around for decades and that still is not even used uniformly across the board for sickle cell,” Arnold said. Sickle cell disease does not meet the strict definition of a rare disease given its prevalence, she added, but its financial burden on the healthcare system rivals that of far smaller patient populations that draw significantly more research investment. Sickle cell disease is an inherited blood disorder caused by a mutation in the gene that produces beta-globin. The mutation causes red blood cells to form a rigid, crescent shape, blocking small blood vessels and triggering vaso-occlusive crises: sudden episodes of severe pain that can require emergency treatment. Vertex Pharmaceuticals’ Casgevy, known generically as exagamglogene autotemcel, is the first CRISPR/Cas9 gene-editing therapy approved in the United States. Educating families comes second, and that work, Arnold and Garrett agreed, depends on storytelling rather than clinical literature to close a longstanding trust gap between Black communities and the healthcare system. Garrett framed it as basic fairness. “I don’t care if you’re poor or if you’re rich,” he said. “The health equity issue is that I should have the same access to the best treatments whether I’m rich or poor,” he said. An estimated 100,000 Americans live with sickle cell disease, which disproportionately affects people of African descent. Roughly one in every 365 Black births in the U.S. is affected. Through the first quarter of 2026, more than 500 of the 60,000 eligible patients worldwide have initiated the months-long Casgevy treatment.

The most important development ... certain rare metabolic or neuromuscular diseases, inherited retinal disorders and some cancers. Gene therapy aims to address disease at a biological level. Depending on the treatment, it may provide a working copy of a gene, silence a harmful gene, alter a genetic sequence, or equip immune cells to recognize ... The most important development is not one universal treatment, but a growing range of approaches designed for particular conditions, including inherited blood disorders, certain rare metabolic or neuromuscular diseases, inherited retinal disorders and some cancers. Gene therapy aims to address disease at a biological level. Depending on the treatment, it may provide a working copy of a gene, silence a harmful gene, alter a genetic sequence, or equip immune cells to recognize cancer. This is especially relevant to selected inherited blood disorders, where corrected blood-forming cells can continue producing healthy blood cells over time. However, the word “cure” should be used carefully because long-term outcomes continue to be studied. Free ConsultationHave questions about your own case? Gene therapy has also been developed for certain inherited retinal diseases, spinal muscular atrophy, primary immunodeficiencies, metabolic disorders and rare neurological conditions. Treatment may be given directly in the body or by modifying collected cells in a laboratory before returning them. Careful long-term follow-up is essential because benefits and delayed side effects must be monitored over time. Medically reviewed by the Acıbadem International Medical Board — August 16, 2026 · Dr. Bahadır Kaynarkaya, MD Dr. Şule Eren, MD · Gene therapy breakthroughs in 2025 are building on approved treatments for selected inherited disorders, cancers and blood diseases, while research continues to improve precision, safety and access. The latest updates in gene therapy in 2025 include continued expansion of clinical experience with approved therapies and further research into safer, more precise delivery. Gene-editing approaches for inherited blood diseases remain a major area of progress, while researchers are also studying treatments for neurological, eye, liver, muscle and immune-system disorders. A key focus is improving how genetic material reaches the right cells.